EC-18

Enzychem Lifesciences Corporation · Phase 2 active Small molecule

At a glance

Generic name	EC-18
Also known as	EC18 Soft-capsule, EC-18 soft capsules, EC-18 Softgel capsule
Sponsor	Enzychem Lifesciences Corporation
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer (PHASE1, PHASE2)
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation (PHASE2)
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia (PHASE2)
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS (PHASE2)
Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers (PHASE1)
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers (PHASE1)
A Safety and PK Study of EC-18 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EC-18 CI brief — competitive landscape report
EC-18 updates RSS · CI watch RSS
Enzychem Lifesciences Corporation portfolio CI